Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

The recurrence rates of Hepatocellular carcinoma (HCC) are high, necessitating novel and effective adjuvant therapies. Therefore, we conducted a phase II study of glypican-3 (GPC3) peptide vaccine as an adjuvant therapy for HCC patients. Forty-one patients with initial HCC who had undergone surgery...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology 2016-05, Vol.5 (5), p.e1129483-e1129483
Hauptverfasser: Sawada, Yu, Yoshikawa, Toshiaki, Ofuji, Kazuya, Yoshimura, Mayuko, Tsuchiya, Nobuhiro, Takahashi, Mari, Nobuoka, Daisuke, Gotohda, Naoto, Takahashi, Shinichiro, Kato, Yuichiro, Konishi, Masaru, Kinoshita, Taira, Ikeda, Masafumi, Nakachi, Kohei, Yamazaki, Naoya, Mizuno, Shoichi, Takayama, Tadatoshi, Yamao, Kenji, Uesaka, Katsuhiko, Furuse, Junji, Endo, Itaru, Nakatsura, Tetsuya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!